patient
copd
frequent
experi
worsen
symptom
includ
increas
sputum
dyspnea
acut
exacerb
copd
aecopd
defin
sudden
worsen
copd
symptom
requir
addit
hospit
sometim
requir
depend
aecopd
sever
patient
hospit
aecopd
impact
qualiti
life
acceler
declin
pulmonari
function
increas
appropri
treatment
need
prevent
frequent
acut
exacerb
hospit
caus
aecopd
includ
bacteri
respiratori
viral
infect
irrit
air
mani
case
exact
caus
aecopd
unknown
also
remain
unclear
caus
aecopd
relat
prognosi
exampl
unknown
whether
prognosi
sever
aecopd
differ
depend
bacterium
viru
identifi
caus
infect
mani
studi
conduct
relationship
prognosi
copd
bacteri
respiratori
viral
pathogen
pseudomona
aeruginosa
suggest
associ
poor
purpos
studi
analyz
aecopd
readmiss
event
determin
whether
prognosi
vari
bacterium
viru
identifi
retrospect
found
patient
diagnos
sever
aecopd
korea
univers
guro
hospit
januari
may
figur
thirtytwo
aecopd
die
hospit
analyz
patient
aecopd
discharg
treatment
mani
studi
aecopd
use
day
standard
readmiss
event
divid
two
group
one
patient
readmit
within
day
discharg
readmiss
within
day
studi
approv
institut
review
board
korea
univers
guro
hospit
studi
retrospect
studi
patient
consent
necessari
maintain
patient
confidenti
aecopd
defin
worsen
patient
respiratori
symptom
beyond
normal
daytoday
variat
sever
aecopd
defin
aecopd
requir
event
includ
follow
criteria
met
patient
previou
spirometri
show
airway
obstruct
ratio
forc
expiratori
volum
first
second
forc
vital
capac
postbronchodil
spirometri
patient
diagnos
sever
aecopd
patient
discharg
treatment
continu
follow
patient
year
old
medic
record
review
analyz
follow
data
age
gender
smoke
histori
comorbid
global
initi
chronic
obstruct
lung
diseas
gold
stage
inhal
use
pulmonari
oral
medic
use
use
home
oxygen
therapi
cultur
polymeras
chain
reaction
pcr
assay
data
identif
bacterium
viru
realtim
pcr
detect
influenza
viru
respiratori
syncyti
viru
parainfluenza
viru
coronaviru
rhinoviru
enteroviru
adenoviru
bocaviru
metapneumoviru
three
frequent
identifi
bacteria
virus
analyz
studi
cultur
pcr
assay
perform
within
hour
admiss
data
analyz
use
spss
softwar
spss
window
ibm
corpor
armonk
ny
usa
continu
variabl
report
mean
sd
categor
variabl
number
percentag
group
variabl
analyz
comparison
two
group
readmiss
readmiss
continu
variabl
compar
use
student
ttest
test
categor
variabl
compar
use
chisquar
fisher
exact
test
fisher
exact
test
use
expect
number
event
compens
bia
differ
baselin
characterist
two
group
perform
propens
score
match
propens
score
calcul
patient
use
multivari
logist
regress
base
covari
variabl
tabl
match
perform
use
nearest
neighbor
method
select
similar
propens
score
perform
match
report
standard
mean
differ
effect
size
express
suitabl
match
propens
score
match
perform
multivari
analysi
use
logist
regress
logist
regress
analysi
assess
use
test
multivari
analysi
analyz
factor
show
meaning
valu
univari
analysi
propens
score
match
p
consid
statist
signific
estim
odd
ratio
or
confid
interv
ci
sever
aecopd
event
led
readmiss
within
day
discharg
propens
score
match
number
event
group
mean
age
year
group
proport
male
higher
femal
group
major
patient
gold
stage
ii
iii
variabl
relat
baselin
characterist
show
statist
signific
differ
two
group
tabl
show
detail
baselin
characterist
two
group
propens
score
match
analyz
pulmonari
medic
use
treatment
admiss
patient
use
inhal
tripl
therapi
commonli
use
type
inhal
group
half
patient
take
mucolyt
agent
oral
steroid
use
patient
oxygen
therapi
home
use
patient
propens
score
match
oral
medic
use
home
oxygen
therapi
greater
readmiss
group
propens
score
match
signific
differ
tabl
show
detail
pulmonari
medic
treatment
data
two
group
propens
score
match
classifi
aecopd
event
bacteri
pathogen
identif
viral
pathogen
identif
coidentif
pathogen
identif
bacteri
viral
infect
identifi
event
propens
score
match
bacteri
pathogen
identif
rate
significantli
greater
readmiss
group
match
differ
statist
signific
signific
differ
variabl
also
analyz
frequent
identifi
infecti
bacteria
virus
sever
aecopd
three
commonli
identifi
bacteria
p
aeruginosa
streptococcu
pneumonia
haemophilu
influenza
three
commonli
identifi
virus
influenza
viru
rhinoviru
parainfluenza
viru
propens
score
match
p
aeruginosa
identif
rate
significantli
greater
readmiss
group
noreadmiss
group
signific
differ
identif
rate
bacteria
virus
match
p
aeruginosa
identif
rate
remain
significantli
greater
readmiss
group
tabl
show
detail
microbiolog
data
two
group
propens
score
match
perform
multivari
analysi
p
aeruginosa
identif
rate
first
adjust
propens
score
variabl
associ
prognosi
p
aeruginosa
identif
rate
higher
readmiss
group
compar
noreadmiss
group
ci
second
adjust
propens
score
variabl
tabl
p
aeruginosa
identif
rate
higher
readmiss
group
compar
noreadmiss
group
ci
tabl
studi
analyz
effect
bacteri
viral
identif
readmiss
patient
sever
aecopd
previou
studi
base
london
show
sever
aecopd
patient
readmit
within
day
discharg
readmit
within
studi
readmiss
sever
aecopd
focus
age
comorbid
inhal
use
psycholog
lack
data
readmiss
focus
bacteri
viral
identif
caus
exacerb
studi
first
demonstr
identif
p
aeruginosa
correl
readmiss
rate
sever
aecopd
p
aeruginosa
gramneg
rod
bacterium
caus
opportunist
infect
caus
agent
infect
mainli
immunocompromis
chronic
lung
diseas
patient
includ
patient
cystic
fibrosi
copd
becom
import
pathogen
increas
immunosuppress
treatment
chemotherapi
use
intens
care
unit
p
aeruginosa
current
common
caus
agent
nosocomi
infect
second
common
caus
agent
ventilatorassoci
pneumonia
p
aeruginosa
infect
difficult
treat
first
p
aeruginosa
innat
resist
mani
antimicrobi
agent
commonli
use
treatment
pneumonia
p
aeruginosa
sever
broadli
specif
multidrug
efflux
system
provid
innat
second
p
aeruginosa
easili
acquir
resist
compar
p
aeruginosa
strain
possess
larg
genom
mbp
produc
multipl
secondari
metabolit
polym
better
quorum
sens
bacteria
allow
spread
acquir
resist
third
p
aeruginosa
secret
virul
factor
impair
immun
system
exampl
p
aeruginosa
secret
elastas
b
escap
p
aeruginosa
also
secret
exoenzym
exo
bifunct
toxin
encod
exo
gene
disrupt
pulmonari
vascular
barrier
result
identif
p
aeruginosa
mean
treatment
complet
erad
difficult
compar
bacteria
antibiot
use
longer
time
durat
hospit
greater
often
lead
secondari
hospit
infect
antibiot
side
effect
studi
p
aeruginosa
commonli
identifi
pathogen
howev
previou
studi
commonli
identifi
bacteria
aecopd
pneumonia
h
influenza
moraxella
reason
discrep
first
copd
grade
studi
high
p
aeruginosa
commonli
identifi
patient
gold
stage
iii
metaanalysi
shown
p
aeruginosa
identif
statist
higher
copd
patient
identif
p
aeruginosa
mean
host
belong
highrisk
group
second
region
characterist
unlik
western
studi
studi
korea
asia
show
p
aeruginosa
commonli
two
clinic
featur
p
aeruginosa
identifi
aecopd
common
featur
carriag
p
aeruginosa
short
time
follow
clearanc
month
featur
persist
colon
p
aeruginosa
debat
regard
prognosi
mortal
stabl
copd
patient
colon
p
clear
evid
antibiot
use
condit
prospect
studi
show
p
aeruginosa
identif
patient
sever
aecopd
associ
higher
mortal
chronic
p
aeruginosa
infect
also
shown
increas
mutat
rate
antibiot
resist
proteas
reduc
although
controversi
regard
p
aeruginosa
infect
patient
stabl
copd
identif
p
aeruginosa
case
aecopd
mean
poor
prognosi
studi
limit
first
retrospect
studi
limit
obtain
data
exampl
patient
lack
chest
comput
tomographi
data
thu
limit
analysi
associ
bronchiectasi
sputum
cultur
assay
conduct
admiss
second
colon
contamin
could
distinguish
studi
although
sputum
result
grade
four
five
use
analyz
cultur
result
collect
specimen
done
train
physician
addit
data
analyz
colon
contamin
lack
third
sampl
size
small
propens
score
match
comparison
analysi
suggest
may
insuffici
statist
power
exampl
bacteri
pathogen
identif
rate
readmiss
group
noreadmiss
group
differ
statist
signific
although
studi
retrospect
singlecent
studi
analyz
variou
factor
largescal
group
addit
largescal
multicent
random
control
studi
requir
confirm
result
p
aeruginosa
infect
sever
aecopd
difficult
treat
secondari
problem
often
aris
p
aeruginosa
infect
occur
mainli
highrisk
patient
sever
aecopd
p
aeruginosa
infect
mean
poor
prognosi
increas
rate
readmiss
